Cipla Ltd.

Cipla is looking to file more than 20 applications seeking approval for its generic medicines from the US health regulator this fiscal. This step will be taken in order to strengthen the execution of its key launches, and building speciality focus in respiratory and Central Nervous System (CNS). The company had filed 32 abbreviated new drug applications (ANDAs) in the US in the last financial year.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries.